The team at GABA Therapeutics is developing GRX-917, a new drug candidate expected to have a broad range of safe and effective therapeutic indications, to transform the lives of patients with life-altering neuropsychiatric, neurologic and pain disorders.
Many of these conditions represent some of the largest unmet medical needs in the United States and worldwide.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.